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ABSTRACT
Objectives Active surveillance (AS) enables men with 
low risk, localised prostate cancer (PCa) to avoid radical 
treatment unless progression occurs; lack of reliable AS 
protocols to determine progression leaves uncertainties 
for men and clinicians. This study investigated men’s 
strategies for coping with the uncertainties of active 
monitoring (AM, a surveillance strategy within the Prostate 
testing for cancer and Treatment, ProtecT trial) over the 
longer term and implications for optimising supportive 
care.
Design Longitudinal serial in- depth qualitative interviews 
every 2–3 years for a median 7 (range 6–14) years 
following diagnosis.
Setting Four centres within the UK Protect trial.
Participants Purposive sample of 20 men with 
localised PCa: median age at diagnosis 64 years (range 
52–68); 15 (75%) had low- risk PCa; 12 randomly 
allocated to, 8 choosing AM. Eleven men continued with 
AM throughout the study period (median 7 years). Nine 
received radical treatment after a median 4 years (range 
0.8–13.8 years).
Intervention AM: 3- monthly serum prostate- specific 
antigen (PSA)- level assessment (year 1), 6–12 monthly 
thereafter; increase in PSA ≥50% during previous 12 
months or patient/clinician concern triggered review.
Main outcomes Thematic analysis of 73 interviews 
identified strategies to accommodate uncertainty and 
anxiety of living with untreated cancer; implications for 
patient care.
Results Men sought clarity, control or reassurance, with 
contextual factors mediating individual responses. Trust in 
the clinical team was critical for men in balancing anxiety 
and facilitating successful management change/continued 
monitoring. Only men from ProtecT were included; men 
outside ProtecT may have different experiences.
Conclusion Men looked to clinicians for clarity, 
control and reassurance. Where provided, men felt 
comfortable continuing AM or having radical treatments 
when indicated. Clinicians build patient trust by clearly 
describing uncertainties, allowing patients control 
wherever possible and being aware of how context 
influences individual responses. Insights indicate need for 
supportive services to build trust and patient engagement 
over the long term.
Trial registration number ISRCTN20141297; Pre-results.
Strengths and limitations of this study
 ► This is the first longitudinal qualitative study to doc-
ument men’s longer- term experiences of an active 
surveillance protocol for localised prostate cancer, 
with 73 interviews conducted over a period of 6–14 
years.
 ► Although the sample size was small (20 men), sam-
pling was led by principles of maximum variation 
in line with guidelines for qualitative research and 
enabled identification of commonalities and differ-
ences across groups.
 ► Findings provide insights into how clinical care for 
men following active surveillance protocols can be 
tailored to support individuals.
 ► Men following active surveillance protocols outside 
the Prostate testing for cancer and Treatment trial 
may have different experiences.
 ► Few men were of a non- white background.
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BACKGROUND
Uptake of active surveillance/monitoring (AS/AM) as a 
management strategy for low- risk prostate cancer (PCa) has 
increased markedly in recent years.1–3 AS/AM offers the 
opportunity to delay or avoid significant side effects associ-
ated with radical treatments.4–6 Yet protocols for AS/AM vary 
and the optimum approach to conservative management 
remains contested, with programmes variably including 
serum prostate- specific antigen (PSA) testing, digital rectal 
examination and/or prostate biopsy with or without multi-
parametric MRI (mpMRI), with the aim of detecting clin-
ical progression for timely curative radical treatment where 
indicated.7–9
AS/AM protocols require men to live with uncertainty 
about the consequences of leaving the cancer untreated. 
Current clinical protocols adopt two premises: first, men 
can request radical treatment if they no longer tolerate this 
uncertainty and/or there is evidence of clinical progression; 
second, this ‘window of opportunity’ for cure may be missed. 
Up to half of men following an AS/AM protocol change 
to radical treatments within 10 years7–10; 30% of changes 
occur without indication of clinical progression.11–13 System-
atic reviews (SRs) of the literature present a mixed picture 
regarding psychological well- being of men undergoing AS/
AM14–17; while most men report positive psychological well- 
being, a minority report short- term heightened anxiety, 
uncertainty and distress. A recent SR of barriers and facili-
tators to selecting and adherence to AS18 reported a range 
of factors affecting adherence, leaving little clarity on how 
to optimise the strategy. Cross- sectional studies report men 
following AS normalise the cancer by ‘screening off’ the diag-
nosis19 or reframing its threat19 20 or actively engage in life-
style changes to ‘do something extra.’19 21 Although there is 
evidence that anxiety is minimal22 or decreases with time on 
AS,23 longitudinal qualitative research on long- term experi-
ences of AS remains scarce. Yet longitudinal studies offer an 
essential insight into how participants’ needs and experiences 
may change over time, particularly as the disease develops 
slowly and patients may need to consider remaining on it or 
changing management over very many years. Longitudinal 
research also enables exploration of sensitive issues as the 
relationship between interviewer and interviewee develops.24
We addressed this evidence gap by conducting a longi-
tudinal qualitative investigation of the experiences of men 
who followed the active monitoring (AM) protocol as their 
primary treatment in the Prostate testing for cancer and 
Treatment (ProtecT) randomised controlled trial (RCT)25 
over a median of 7 (range 6–14) years. We investigated men’s 
experiences of uncertainties and strategies to manage this. 
Findings provide insights to shape clinical services for the 
increasing numbers of patients now undergoing AS/AM 
programmes for clinically localised PCa.
METHODS
ProtecT study
The ProtecT RCT compared radical prostatectomy (RP), 
radical radiotherapy (RT) and AM for clinically localised 
PCa diagnosed following PSA testing in men identified 
in primary care.6 9 25 Men declining randomisation were 
offered identical follow- up, forming a comprehensive 
cohort.26 ProtecT AM aimed to allow men to avoid or 
delay radical treatment and its side effects unless their 
PCa progressed. It involved monitoring with PSA tests 
every 3 months for 1 year, then every 6 or 12 months there-
after, with an annual review. If PSA rose by 50% or more 
in a 12- month period or any concerns were raised by the 
patient or clinician at any time, there could be a re- eval-
uation of cancer status which could lead to continuing 
AM or changing to a radical option. This is described 
in detail elsewhere.9 25 A model of nurse- led, urologist- 
supported care was developed for delivery of AM.27 Men 
were informed of uncertainties: while the intention was to 
offer radical treatment when evidence of cancer progres-
sion was identified, progression might occur undetected 
and opportunity for cure be missed; and there was little 
evidence on effective strategies for monitoring. Uncer-
tainties with AM were expected to be similar to those 
experienced with other AS strategies because of the lack 
of international consensus on protocols.28
Longitudinal interview study
This study was part of a larger, longitudinal interview 
study, investigating men’s experiences of treatment 
received within the ProtecT study and including partici-
pants following each of the treatment pathways (AM, RT, 
RP) with a median follow- up of 10 years.29 In total 88 men 
were invited, and 65 men took part in one or more inter-
views. Experiences of men following an RT pathway have 
been submitted for publication elsewhere.30
Participants
Of those recruited to the longitudinal interview study, 20 
men were recruited at diagnosis, chose or were randomly 
allocated to follow an AM pathway and took part in three 
or more interviews; their data are reported here. ProtecT 
study participants undergoing AM as their primary 
management following random allocation or treatment 
choice and within 12 months of PCa diagnosis were 
eligible for this prospective interview study; this included 
men with clinically localised or intermediate/high- risk 
disease in line with eligibility criteria for the ProtecT 
RCT.29 Purposive sampling was used with the aim of 
obtaining a maximum variation sample for this interview 
study in terms of participant characteristics identified a 
priori as potentially impacting on experiences: age, socio-
economic background, whether randomly allocated to or 
choosing AM, and with low- risk or intermediate/high- risk 
disease. Recruitment took place at four of nine ProtecT 
centres to capture as diverse a range of experience as 
possible, while limiting time required for travel by the 
interviewer. Three centres were located across England 
and one was in Wales, UK.
Men received a written invitation explaining the 
purpose of the longitudinal interview study embedded 
within the RCT, followed by a telephone call establishing 
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willingness to participate.29 Five men consenting to the 
interview study at time of PSA testing were diagnosed with 
localised PCa and underwent AM. Twenty- one further 
men were invited following diagnosis and random allo-
cation or treatment choice; 15 agreed, giving a total of 
20 participants consenting to take part in the interview 
study (table 1). Two men refused, four did not respond 
and six were ineligible due to receiving treatment outside 
the ProtecT study or because more than 12 months had 
passed since management by AM had begun.
Data collection
First interviews were scheduled around 6 months after 
men started AM, subsequent interviews at 2–3 yearly 
intervals. Data collection commenced in 2000 and final 
interviews took place in 2014. Most were conducted by 
JW, a social scientist with experience in qualitative health 
services research, with a small number conducted by 
LS, a research nurse within the ProtecT study or by LB, 
a social scientist with experience in qualitative health 
services research (see the acknowledgements section). 
All initial interviews took place face to face to put inter-
viewees at ease, in the location of their choice in homes, 
hospital outpatient departments or university premises 
as preferred. Subsequent interviews were face to face or 
by telephone according to interviewee preference. Inter-
views lasted an average of 50 min (range 8–123 min). 
All were audio- recorded with consent and transcribed 
verbatim, at which point identifying data were removed 
or disguised. Partners could contribute where requested, 
following the same consent process.
Interview topics are shown in online supplementary 
appendix A. These were derived from the literature prior 
to data collection but subsequently informed by data 
collection. Topic guides were tailored to fit experiences, 
for example, questions regarding experiences of radical 
treatments were included for those changing manage-
ment. Interviews were therefore in- depth and flexible, 
with prompts used to explore areas of interest, while 
allowing individuals to introduce content of relevance to 
them. Field notes were made in tandem with audiodata 
collection and analysed in parallel with transcript data.
Data analysis
Thematic analysis was used, applying principles of constant 
comparison based on grounded theory.31 Data collection 
and analysis proceeded iteratively, enabling preliminary 
findings to inform further data collection. Eight initial 
interview transcripts were coded and themes identified 
independently by JW and LS (see acknowledgements) for 
subsequent cross- comparison of codes/themes, to refine 
the topic guide and inform further sampling and data 
collection. Disagreements were resolved by discussion to 
reach consensus. Analysis proceeded by comparing data 
between groups within the sample to identify common-
alities and contrasts of experience according to group. 
Groups included those accepting random allocation or 
choosing AM; remaining on AM or changing to radical 
treatment; with lower and higher risk disease; older or 
younger at diagnosis; and in earlier and later interviews 
to explore how views and experiences evolved over time. 
Data analysis was supported by qualitative data software 
NVivo.32 Coding carried out in NVivo enabled rapid 
retrieval of coded data for systematic comparison across 
participants and time.32 33 The standards for reporting 
qualitative research33 were applied in reporting this study. 
Interpretations of study data were regularly discussed 
by JW and JD to counter risk of overinterpretation of 
findings.
Patient and public involvement
The ProtecT study was awarded funding in 1999, with 
further funding awarded in 2006, at a time when patient 
and public involvement (PPI) was relatively new and 
the original protocol did not explicitly outline PPI 
Table 1 Characteristics of interview study participants 
n=20
 
Accepted random 
allocation
Chose 
treatment
n=12 n=8
Age
  50–59 years 2 1
  60–69 years 10 7
Social class
  Managerial/professional 5 4
  Other 7 3
  Missing 0 1
Study centre
  1 1 1
  2 3 0
  3 6 7
  4 2 0
D’Amico risk category*
  Low 8 7
  Intermediate/high 3 1
Timing of switch to radical treatment (n=9)
  0–5 years 2 3
  >5 years 2 1
  >10 years 1 0
N interviews during AM
  1 0 1
  2 3 1
  3 8 5
  4 0 0
  5 0 1
  6 1 0
*Data missing for one participant.
AM, active monitoring.
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work. However, early qualitative work led to changes in 
patient information provision.34 In addition to findings 
reported here, qualitative interviews elicited participant 
experiences on study processes resulting in changes, 
for example, making patient questionnaires available 
electronically. Study participants contributed to written 
patient summaries of the ProtecT trial findings dissem-
inated in 20166 9 and key findings of the study were fed 
back to ProtecT study participants (including some who 
took part in the interview study) in face- to- face meetings 
in June 2017, when participants were consulted on how 
to optimise further dissemination of the trial findings to 
men newly diagnosed with PCa.
RESULTS
Twenty participants (median age at diagnosis 64 range 
52–68 years) were interviewed a minimum three and 
maximum six times, with 73 interviews conducted over a 
median of 7 (range 6–14) years follow- up. Nine (45%, 5 
with low- risk disease) underwent radical treatment after 
a median of 4 years (range 9mo- 13yr9mo) follow- up, 
comparable with the ProtecT study9 Eleven (10 with 
low- risk disease) continued with AM for a median of 7 
years (range 6–7 years) follow- up (table 1). Comparison 
of baseline characteristics to those of men in the main 
ProtecT study35 showed broad similarities: median age 
was 64 year (main study: 63 year); 9/20 (45%) were in 
managerial occupations (main study: 46%); 15/20 (75%) 
had low- risk disease (main study: 72%).
Comparison of experiences across these groups showed 
more commonalities than differences, suggesting that the 
themes were relevant to men following AM. Five men with 
intermediate/high- risk disease expressed similar views to 
those with low- risk disease. There was a suggestion that 
higher risk men changed management sooner than those 
with low- risk disease, but this will be more comprehen-
sively investigated in a future ProtecT study paper.
Men highlighted the paradox of receiving a potentially 
life- threatening diagnosis without experiencing symp-
toms. Some viewed this positively: there was no functional 
impact on their life. For most it brought uncertainty, the 
possibility of cancer progression without tell- tale signs. 
Uncertainty about future cancer progression merged with 
uncertainty about the ability of AM to detect progressing 
disease in time to initiate curative treatment (table 2). 
Men responded by looking for clarity, control and reas-
surance. Contextual factors mediated choice of response 
for individual men and over time. Where men’s needs 
were met, trust in health professionals grew.
Strategies: seeking clarity, control and reassurance
Men employed strategies broadly categorised under three 
themes: clarity, control and reassurance. Themes and 
strategies were partly complementary and yet potentially 
in tension: the active search for clarity or control could 
potentially conflict with the acceptance required to take 
on reassurances and superficially opposing behaviour 
might be motivated by the same underlying desire for 
control (table 3). Strategies were employed iteratively 
and in parallel, with reliance on specific strategies varying 
between individuals and over time (figure 1). Seeking 
clarity and control were strategies often employed early 
in the monitoring process. Men expressed a greater sense 
of reassurance as time passed, unless they lost confidence 
in the monitoring process (see below).
At diagnosis, the most common strategy was to gain 
clarity to reduce uncertainty. Men questioned health 
Table 2 Response to diagnosis: managing uncertainty
Absence of 
symptoms
I just carried on a normal life. And my work and my well- being wasn’t affected. I had none of the classic 
symptoms at all.
P8- Pref- H, Int +3 mo, radical treatment +2yr11mo
Uncertainty about 
prognosis
You’ve got this thing growing inside you and you know, it’s not as if it’s somewhere like outside of you 
where you can feel a lump or something like that, you just don’t know what’s going off.…I think that it 
would be true to say that I feel my life has been invaded, I view the cancer as like, an invasion of my life.
P6- Pref- L, Int +1yr9mo, radical treatment +8yr11mo
When I first went for the active monitoring I thought well, this isn’t going to be a problem, I’ll be able to sail 
through this. Because I know that it’s contained and I know I’m being monitored, so if there’s anything that 
suddenly changes, which needs a different route, then we’re there, we’re ahead of the game. But then it 
wasn’t, in reality, as simple as that, because, I then knew, because I’d been diagnosed, that I had cancer 
and it messes things up a bit, you know? You think you can handle it, but it’s always there niggling away in 
your mind.
P19- Pref- L, Int +7 mo, continued AM
Uncertainty about 
AM protocol
What’s the danger level any rate? What is the danger level? So, I don’t really know I mean they say that by 
this blood test they can tell if it’s suddenly come active or not. I don’t know, can they?
P18- Pref- L, Int +6 mo, withdrew from AM+7 year
continued AM, continued AM throughout period of follow- up; H, high risk; I:, Interviewer; I, intermediate risk; Int+1yr1mo, timing of interview 
was 1- year 1- month postdiagnosis; L, low risk; P:, patient; Pref, chose treatment; Radical treatment+4yr4mo, radical treatment initiated 
4years 4 months postdiagnosis; Rx, randomly allocated to treatment; Unknown, missing data; W:, patient’s wife; withdrew from AM +7yr post 
diagnosis, withdrew from AM 7years post diagnosis.
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Table 3 Strategies for managing uncertainty: seeking clarity, control and reassurance
Clarity
Search for clarity on 
triggers for active treatment 
repeatedly foregrounds 
uncertainty and the need to 
trust
P: [Research nurse] said ‘We’ve got parameters to follow and if those parameters are fulfilled—or you fall outside 
those parameters, we would—the alarm bells would ring and we’d do something about it’. I suppose I should be 
reassured with that.
I: Are you clear on what those parameters are? Or, do you feel like you know what those parameters are?
P: No, no, no.
P11- Rx- L, Int +2yr1mo, continued AM
The basic reason the ProtecT study is running is because there is no kind of definite knowledge about the 
outcome of either of the treatments and yet that is what it is all about. And that is all that the ProtecT study is 
trying to deduce. So, everybody can be only as helpful as they can be. They can't then tell me things that they 
don’t know.
P20- Pref- L, Int +5 mo, continued AM
Control
Careful choice of language 
showing influence of words 
used by health professionals.
He [urologist] said, ‘Believe you me, at the moment it’s dormant’ and he said, ‘Personally speaking he said, I 
don’t think it’s anything to worry about’. He said you may have had that a long, long, long, long time
P18- Pref- L, Int +6 mo, withdrew from AM+7yrWell, it was explained to me it was only a small, small bit you know, 
nothing to worry about, it hadn't spread, or weren't going to spread or you know, at least that's the sort of words 
that they used.
P16- Rx- L, Int +2yr1mo, continued AM
Choosing who to tell/when 
to talk about diagnosis
We never told anybody, except I think we told one of the children. I thought we ought to do that, I wouldn’t tell 
anybody at all. P11- Rx- L, Int +6 mo, continued AM
I don’t want all and sundry knowing, you know, that this is around because everybody would be coming up 
to me and saying, ‘How’re you doing?’ or whatever else. Those that I have told know how I feel about it, I’ve 
told them that I don’t want to talk about it, that it’s just one of those things I’ve got to get on with and should I 
deteriorate to the point where it affects them, I’ll tell them.
P4- Rx- I, Int+9 mo, Radical treatment +4yr5mo
I don’t talk to people about it, I don’t like to. I like to call myself healthy ‘cos I think talking about it pulls me down 
a little bit, with mates and that.
P17- Pref- L, Int +2yr1mo, continued AM
Determining frequency 
of PSA tests: −3- monthly 
tests to act fast if needed. 
−6- monthly tests to control 
how often thoughts of PCa 
intrude.
Preference for 3 monthly PSA tests
I’d rather have it taken every three months just to make sure, where we are. I wouldn’t like to go out further than 
three monthly, at the moment. I have been asked if I wanted it to go out for six monthly but no, the way things 
are, I’d rather keep it 3 monthly.
P12- Rx- L, Int +1yr11mo, continued AM
Preference for 6- monthly tests
I have to put it away in a box and put it away for every three months and then you think about it every 
three months, you know? So, six months is good because you’ve got a longer period of time, now. And it just 
goes, you don’t think about it day to day.
P13- Rx- L, Int +2yr1mo, continued AM
Timing of test relative to start of month
I’ve been coming in for the test at the end of the month and I’ve just asked can my appointment be put at the 
beginning of the next month because psychologically, you know. During May, waiting for the 22nd of May, I’ve 
not been too clever. That maybe answers some of how I am feeling, you know, that month is not good and yet 
I’ve got to wait now til next week to find the result but, you know, it’s very, a very anxious time.
P4- Rx- I, Int+9 mo, radical treatment +4yr5mo
Choosing which healthcare 
professional is seen or 
whether face- to- face or 
telephone. Preference 
for face- to- face contact 
Evidence of change with 
time as trust increased
Preference for face- to- face visits
P: Because they said, they could do it on the phone, but I said, I don’t mind going over there.
I: So is that that you actually prefer to go over there than do it on the phone?
P: I do prefer to go over to be honest, well I just feel more, more at ease
P17- Pref- L, Int +2yr1mo, continued AM
Contrast comment 2yr10mo later
She said I think you could go for 6 months now, so I agreed with her
P17- Pref- L, Int +4yr11mo, continued AM
I deal with the same person all the time. But that’s just me. And the phone didn’t work
P13- Rx- L,+2yr1mo, continued AM
Contrast with comment 3 year later
The nurse said give it [telephone review] a try, she said it’s about time, basically, and she said you will give it a try 
and I'll ring you at that time on that day and she rang me at that time on that day, so it worked quite well actually, 
because I'm not one to say a lot on the phone
P13- Rx- L, Int +5yr1mo, continued AM
Continued
6 Wade J, et al. BMJ Open 2020;10:e036024. doi:10.1136/bmjopen-2019-036024
Open access 
professionals, particularly family physicians, urologists 
and research nurses, about ‘triggers’ for active treatment. 
This inevitably highlighted the uncertainties surrounding 
the AM protocol (table 3 and figure 1). In parallel with 
the search for clarity and at times in direct response to 
the multiple uncertainties it revealed, men also sought 
control (figure 1). Ways of seeking control included 
choice of terminology to describe the cancer, influ-
enced strongly by health professionals’ language; who 
to tell about the diagnosis and when to discuss it. Super-
ficially contradictory behaviours were motivated by this 
desire for control. During year 1 postdiagnosis, the AM 
protocol recommended 3- monthly testing. Men rapidly 
identified their 3- monthly PSA tests as a time when uncer-
tainty and anxiety peaked and so developed contrasting 
ways to control their anxiety (table 3): some requested 
ongoing 3- monthly PSA tests, believing this gave better 
odds for controlling disease progression; others explicitly 
requested 6- monthly intervals or testing at the start of the 
month to control how often thoughts of PCa intruded. 
Some requested face- to- face appointments with the same 
health professional; others asserted control by plotting 
their own graphs of PSA values over time. Men (some 
with partner support) modified their exercise routine 
or diet or quit/reduced smoking/alcohol consumption. 
Crucially when men were supported to assert control 
confidence in the monitoring process grew and need for 
control dissipated (table 3, figure 1).
At the same time, this impetus to gain control was partly 
frustrated by ongoing uncertainties surrounding prog-
nosis and the ability of the AM protocol to distinguish 
between indolent and progressing disease. Repeatedly 
facing this realisation, men described a parallel impera-
tive to accept reassurances and invest trust in the health-
care team, particularly the urologist and research nurse. 
Men’s accounts revealed a constant tension between strat-
egies, oscillating between the search for clarity, control 
and reassurance. (table 3, figure 1). Although many men 
reported increased ability to accept reassurances with 
time, choice of strategy was also mediated by various 
other contextual factors.
Plotting PSA values on 
graphs to ‘demonstrate a 
trend’
Once a year I go to [hospital] and they give me a graph there to follow the route of things
P14- Rx- L, Int +4yr9mo, continued AM
It is demonstrating a trend. You see as a [profession] I do a lot of monitoring of [physical trend]. Now I have the 
same sort of problems with [physical trend]. They either open or close all the time, which is then not a problem, 
because it is not getting worse, but if there is a trend then you know that you need intervention to stop it from 
going off.
P19- Pref- L, Int +4yr11mo, continued AM
Controlling diet or engaging 
in exercise or wanting info 
on what diet changes to 
make
I won’t go for the steak, definitely not, it’ll be more, 9 times out of 10 now it’ll be the fish, so it’s that that kind of 
change really. It’s definitely kicked in since [diagnosis]
P4- Rx- I, Int+9 mo, radical treatment +4yr5mo
P: I started taking some Lycopene tablets
W: And also buying tins of tomatoes. Just read bits and pieces. And broccoli.
P: I’ve always ate broccoli
W: I know but I’m just trying to push it in a bit more. But I suppose If you’re being honest, we have looked at diet
P13- Rx- L, Int +4 mo, continued AM
Reassurance
Looking for reassurance and 
developing trust
Knowing, I think knowing once you’re in the, in the circle, you know you’re in with, this system, you feel perhaps 
that you’re part of it and that, you know, everyone says that if you get any problems just ring us up, and you can, 
you know, you can be done tomorrow
P9- Pref- L, Int +5 mo, radical treatment +3yr4mo
I know the ultimate decision is mine whichever way we go. But I usually let them lead me, guide me, if they are 
not showing any signs of any panic or whatever then it is fine as far as I am concerned.
P12- Rx- L, Int +6 year, continued AM
For key see table 2.
PCa, prostate cancer; PSA, prostate- specific antigen.
Table 3 Continued
Figure 1 Strategies to manage uncertainties.
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Contextual factors
A range of contextual factors were identified as medi-
ating to what extent individuals accepted reassurances 
and developed trust in the healthcare team. The clearest 
contextual factor identified was time and all men reported 
that anxiety lessened with time on AM (table 4). Men who 
felt their needs for clarity and control were addressed, 
reported increased ability to place trust in the team with 
time. This was most evident in how men’s preferences 
regarding timing and manner of regular PSA testing 
changed over time with support from health profes-
sionals: some came to accept longer intervals between 
tests or telephone consultations to replace face- to- face 
contact (table 3). Significant caring responsibilities 
gave men other priorities and made them less inclined 
to engage fully with monitoring or request radical treat-
ments (table 4). Other contextual influences included 
the number of social or work commitments individual 
men were juggling, with busier men arguing they had 
little time to feel anxious about AM (table 4). In addition, 
close friends or family members with negative experi-
ences of cancer could raise levels of concern or a sense 
that action was required to control the disease (table 4).
Development of trust
Where men’s needs for clarity, control and reassurance 
were met, trust in the healthcare team grew despite the 
inherent uncertainties and they continued with moni-
toring (tables 4 and 5). A trusting relationship with health-
care professionals was pivotal in maintaining this balance. 
Men who reported higher levels of anxiety at diagnosis 
and ongoing, but who nonetheless continued with AM 
throughout the study, all developed and retained a sense 
of trust in the healthcare team.
By contrast, failure to develop trust, or loss of that trust, 
usually resulting from unclear or contradictory messages, 
tended to lead men either to seek clarity by requesting a 
second opinion or, more commonly, reassert control by 
pressing for radical treatments or, in one case, withdrawing 
from monitoring (table 5). One man, who withdrew from 
Table 4 Contextual factors
Influence of time in 
developing trust
Well, it’s in your mind all the time you’ve got it like, you know, and was it going to flare up and as the 
years went on like and I’m still here, and I’m still here, I’m still here, you know, it got less like. That you 
know and well I’m now 78, I’m thinking, well, I’ve not done bad.
P1- Rx- L-8, Int +13yr5mo, radical treatment +13yr9mo
Well not so bad really, you know I’ve had this condition now 6 years or so and you more or less get used 
to it, you get immune to it really. Yeah, so it's not so bad… It has got easier, you know when I first knew 
that I had it, it was a worry sort of thing you know, but it hasn't got so much a worry over the years.
P15- Rx- L-3, Int +8yr2mo, continued AM
Over the three years it’s been ok, and I’ve been, as far as I know they’ve really taken quite good care of 
me, they’ve given me plenty of time, I can ring up any time I want if I was worried about anything. I’ve got 
that, and I feel there’s a contact there that I can ring and have a chat to somebody if I needed to.
P14- Rx- L,+2yr10mo, continued AM
Influence of caring 
role
She was wanting me to go and have this test done or something I don't know what it's called. I said to 
her not at the moment because I'm a bit busy and with the wife and everything, you know, it's been a bit 
awkward.
P18- Pref- L,+6yr2mo, withdrew from AM follow- up +7 year
Social context I’ve got a pretty busy sort of life with my work and what I do within the village and stuff like that. So I 
ain’t got time to brood on it, to be honest. So, yeah, get an active life might help some people. If you’re 
not really, I can imagine if you were just sat around and not really a social sort of person or whatever and 
getting out and around and stuff, that you could sort of vegetate and brood on it a bit, perhaps.
P14- Pref- L, Int +4yr9mo, continued AM
Well basically you don’t think about it at all…well there’s never a day that goes by you’ve got something 
to do, you know, two children, our two children, one is thirty odd and twenty- well nearly thirty. But like 
today I’ve just been down, his boiler’s gone out, and so it goes on, there’s always plenty to do
P9- Pref- L, Int+9 mo, radical treatment +3yr4mo
Family and friends’ 
experiences
I’m in a [name of club], we’re all old people, I mean about 6 people got it [PCa]. And they’re all sort of 
saying that their readings started to shoot up, so I thought I would nip it in the bud then, get it out early. 
All of them had treatment. Some of them had had surgery first, then radiotherapy, and for some of them 
that didn’t work either so they’re on hormones again. So I thought well, get it now, so I don’t have to go 
through all this lot.
P9- Pref- L, Int +4yr5mo, radical treatment +3yr4mo
I just lost my sister- in- law this week to breast cancer and it is horrible…It was really horrible, and I 
thought, ‘I don’t wanna go through that’, I don’t wanna be like that
P15- Rx- L, Int +2yr10mo, continued AM
For key see table 2.
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ProtecT AM and the interview study at the time of his 
third interview, reported loss of trust in healthcare profes-
sionals, loss of confidence in the monitoring process and 
a wish to focus on caring for a family member. Two men 
requested radical treatment when it was not clinically 
indicated under the AM protocol; both reported contra-
dictory messages from healthcare professionals and a lack 
of trust in the advice they received. These responses were 
an assertion of control in the context of loss of trust.
DISCUSSION
This study of men’s long- term experiences in following 
the ProtecT AM protocol for localised PCa found that 
men sought clarity, control and reassurance in order to 
deal with the uncertainties they faced, and developed 
trust in healthcare professionals when these needs were 
recognised and met. At the time of diagnosis, many 
sought clarity about ‘triggers’ for management change. 
They also sought control in apparently contradictory 
ways: over who knew their diagnosis, PSA test timing 
or manner, and over lifestyle choices. Given ongoing 
uncertainties, they sought reassurance from the clinical 
team and, where trust developed, monitoring became 
acceptable and normalised. Lack or loss of trust, arising, 
for example, through conflicting information or failure 
to accommodate attempts to control anxiety, led men 
to reassert control through, for example, requests for 
radical treatment or withdrawal from follow- up. Contex-
tual factors influenced responses: caring responsibilities 
discouraged men from further investigations or radical 
treatment; friends or relatives with advanced cancer 
encouraged discussion about radical treatment. Crucially, 
where trust developed, even those experiencing higher 
levels of anxiety felt able to continue with AM where 
indicated.
This study is unique in reporting prospective data 
collected over a mean period of 7 (range 6–14) years, inves-
tigating experiences of a standardised AS/AM protocol, 
with a large dataset: 73 interviews among 20 men from 4 
centres, each man interviewed at least three times. The 
longitudinal design captured how men’s strategies and 
contextual factors changed with time and the pivotal role 
healthcare professionals could play in facilitating strate-
gies and developing trust. The sample included men with 
low and intermediate/high- risk PCa, those randomly allo-
cated to and those who chose AM, from a range of study 
sites, with a range of ages at diagnosis and both those 
continuing with AM and those undergoing radical treat-
ments. More commonalities than differences were found 
between these groups.
Limitations include the fact that ProtecT study partic-
ipants may have been positively oriented to AM, having 
accepted allocation to or chosen this pathway. They 
received RCT follow- up from ProtecT study research 
nurses and urologists involved in the study, rather than 
in routine clinics. It has been documented elsewhere that 
men valued the flexibility, accessibility and continuity 
of nurse- led AM27; this may have influenced the devel-
opment of trust for the men in this study. Men outside 
the study, following different AS/AM protocols may 
report different experiences, although all face the same 
uncertainties regarding disease progression and need to 
balance control and trust. Only one man in this interview 
study reported withdrawing from AM; others withdrawing 
from AM may have had different experiences. Few men 
were from a non- white background.25 All men started 
AM as their primary treatment. Of the nine patients who 
changed management, seven did so in response to clinical 
advice to initiate treatment in line with the AM protocol; 
only two patients changed management due to rising 
anxiety in the absence of such evidence. Most (n=15 or 
75%) were diagnosed with low- risk PCa at baseline and 
around half (n=11) remained on AM throughout. Men 
with intermediate- risk/high- risk disease expressed similar 
views to those with low- risk disease. The overall sample size 
(20) limited scope for comparing experiences according 
to key criteria used to obtain a maximally diverse sample. 
However, comparison of experience across groups showed 
more commonalities than differences, meaning that find-
ings reported here may be relevant to those following 
AM and potentially AS. In a parallel study,30 men sought 
clarity about whether their radiotherapy treatment had 
been successful, but issues of control and trust had less 
salience in the longer term than they did for men on AM, 
who faced an ongoing need for clarity, control and trust 
to prevent a premature move off AM.
AS/AM has been recommended as the best option 
for men with low risk, clinically localised PCa in clinical 
Table 5 Illustrations of loss or lack of trust
Conflicting 
advice
I was getting very confused…people saying you should have it [radical treatment] another one saying you 
shouldn’t have it and another one saying you should have it and then one, I saw this radiology, radiologist 
whatever and he said ‘well what do you think?’ and I said ‘what do I know?’ I said, ‘I’m seeing you, I’m expecting 
you to tell me!’ and after a while he said ‘well yes, perhaps you should then’. You know and you think well should I 
or shouldn’t I? Really, I suppose my own [family] doctor at the time said, ‘Well I would have it’.’
P5- Rx- Unknown, Int +5yr5mo, radical treatment +4yr4mo
Lack of 
trust
So I mean really speaking it [AM] hasn’t done a lot of good at all has it? So, I don’t really know if this blood thing, 
this PSA does the trick or not.
P18- Pref- L, Int +2yr5mo, withdrew from AM+7y
For key see table 2.
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guidelines.36 This is the first report to our knowledge, 
using longitudinal qualitative methods to illuminate 
men’s experiences of undergoing this over such a long 
period. It highlighted men’s need for clarity of infor-
mation to support shared decision making about PCa 
treatment options and the benefits their wish for control 
may have in promoting engagement in shared decision 
making and healthy lifestyle choices as reported else-
where.37 38 Participants in this qualitative study reported 
raised anxiety, peaking at PSA testing, with varying 
intensity between men. ProtecT study patient- reported 
outcomes overall showed no greater anxiety among men 
randomised to AM than RP or RT at any time up to 6 years,6 
but these were summary measures of patient groups, and 
questionnaires were completed annually, not necessarily 
at the time of PSA testing. Previous qualitative research 
suggests that uncertainty and anxiety are issues for men 
on AM/AS14 15 19 and may influence decisions to initiate 
radical treatments. Research has also suggested anxiety is 
highest at the time of diagnosis rather than during moni-
toring.6 23 39 All men in this study acknowledged uncer-
tainties and most acknowledged some anxiety at some 
point. However, it was notable that men reporting greater 
or persistent anxiety did not necessarily request change 
in management; anxiety could be managed successfully 
using coping strategies and reassurance from trusted 
health professionals. Previous research has shown men 
respond to surveillance by normalising, ‘bracketing off’ 
their cancer or striving to do ‘something extra’19 21 and 
has highlighted the importance of clarity of informa-
tion and trust in the information provided for men.37 38 
These strategies and findings were replicated here, but 
a novel finding here was men’s careful balancing of the 
need for clarity, control and reassurance and the key role 
of healthcare professionals in meeting these needs and 
developing trust.
Rapid increases in numbers of men receiving AS/
AM for low- risk or low- volume intermediate risk PCa 
in the USA and UK1 2 have occurred without evidence 
or consensus on inclusion criteria or optimal proto-
cols.18 28 Around 9% of patients change to radical treat-
ment annually,9 10 13 many without evidence of cancer 
progression.7 11 13 This study indicates that men need 
care that respects their capacity to exercise control in 
line with their own coping strategies, and clear, consis-
tent messages from health professionals are needed 
to develop and maintain trust. Health professionals 
supporting men following AS/AM should be aware 
of strategies that men adopt, the influence of contex-
tual factors on men’s decision making, and their own 
pivotal role in meeting men’s needs and in building 
and retaining trust, if they are to tailor care to meet 
individual needs. Understanding the benefits to 
patients of clarity in communication and facilitating 
control where possible and an appreciation of the 
role of contextual factors will be essential for health-
care staff to build the trust required for long- term 
monitoring/surveillance.
Clear protocols for AM/AS are needed to provide men 
with information about indicators of disease progression 
and triggers for management change, as well as areas of 
uncertainty. In future, greater accuracy identifying indi-
cators of disease progression may be provided by use 
of mpMRI and targeted biopsies to identify clinically 
significant disease. Further research is needed into the 
optimum ways of reassuring men in order to keep them 
engaged with AS/AM where appropriate.
CONCLUSIONS
Men in the ProtecT RCT sought clarity, control and reas-
surance to accommodate anxiety over uncertainties of 
living with untreated PCa over a median of 7 years of AM. 
Where needs were met, men developed trust in health-
care professionals, this trust being essential in supporting 
men to continue with AM or change management when 
indicated. Clinicians can best build patient trust by being 
open and consistent in describing the certainties and 
uncertainties of the AM/AS protocol, allowing patients 
to exercise control where possible and being aware of 
contextual factors that may influence men’s responses. 
Requests for radical treatment without evidence of 
cancer progression or withdrawal from AM were attempts 
to reassert control when trust failed: maintaining trust 
was pivotal in supporting men to stay with monitoring 
or change management when progression occurred. 
Robust follow- up protocols, including new developments 
in markers and imaging, to provide guidance for health 
professionals and patients about the detection of early 
disease progression, triggers for management change, 
and to provide confidence about when to continue with 
monitoring are under investigation. Insights from this 
study will remain critical for optimising clinician care that 
dovetails with individual men’s needs and enables them 
to remain engaged with AS/AM.
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